How Enterprise Architecture is Reshaping Modern Medicine
Pharma IQ
OCTOBER 10, 2024
Discover how Enterprise Architecture is transforming healthcare operations, enhancing patient care, and addressing technical debt in the industry.
Sat.Oct 05, 2024 - Fri.Oct 11, 2024
130 
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
Fierce Pharma
OCTOBER 8, 2024
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.” In declaring the end of the shortage, the FDA has halted the ability of compounding pharmacies to manufacture the in-demand products.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The 2024 PharmaVoice 100
PharmaVoice
OCTOBER 8, 2024
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
Video: Why the FTC’s Lawsuit Against PBMs May Have Some Legs
MedCity News
OCTOBER 7, 2024
Months before the FTC sued the three largest pharmacy benefit managers, the CEO of Blue Shield of California battled its PBM – CVS Caremark – to bring a lower cost prostate cancer drug to its members. The post Video: Why the FTC’s Lawsuit Against PBMs May Have Some Legs appeared first on MedCity News.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
CPHI Milan 2024: What Does the Future Pharma Workforce Look Like?
PharmaTech
OCTOBER 10, 2024
Five speakers discussed the impact of the COVID-19 pandemic, the rise of artificial intelligence, more women in leadership tracks in the industry, and various emerging technologies.
Pfizer, bracing for Hurricane Milton, pledges aid to emergency services and health support
Fierce Pharma
OCTOBER 8, 2024
Editor's Note: Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub in Tampa, Florida, in 2021—is setting out to bolster emergency services, pool donations and ease medical supply needs as Hurricane Milton touches down this week.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Can AI Reduce Healthcare Disparities? Health Execs Debate
MedCity News
OCTOBER 10, 2024
During the Reuters Total Health conference, two healthcare leaders debated whether AI has the potential to reduce healthcare disparities. One argued that the technology is not there yet, while the other argued that it’s about how people use AI. The post Can AI Reduce Healthcare Disparities? Health Execs Debate appeared first on MedCity News.
Building Rapport In Sales Is An Essential Selling Skill – Here’s Why
Integrity Solutions
OCTOBER 8, 2024
Building rapport in sales is essential for establishing trust and fostering long-term relationships with clients. While technology has made it easier than ever for buyers to access information, B2B buyers in particular are looking for insights and advice from a salesperson they can trust and who they believe has their best interests in mind to help them make good decisions.
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
Fierce Pharma
OCTOBER 7, 2024
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.
First real-world study reveals encouraging efficacy for cell therapy
European Pharmaceutical Review
OCTOBER 7, 2024
New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials. For example, of the 236 patients who received infusions of ciltacabtagene autoleucel (cilta-cel), data shows that 89 percent responded to the treatment.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rural Healthcare Needs More Than Just Telehealth
MedCity News
OCTOBER 6, 2024
People working the most vital occupations, like farmers and ranchers, call the most remote areas in this country home. Their health shouldn’t suffer due to their choice of employment. The post Rural Healthcare Needs More Than Just Telehealth appeared first on MedCity News.
Advancing Precision Care For All
pharmaphorum
OCTOBER 9, 2024
Advancing Precision Care For All with Hakim Yadi from Closed Loop Medicine. Listen to the latest podcast episode featuring insights from a leader in the healthcare industry.
AstraZeneca heads to regulators after Airsupra asthma trial stops early thanks to 'overwhelming efficacy'
Fierce Pharma
OCTOBER 7, 2024
After winning a first-in-class nod for its two-drug inhaler Airsupra l | After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity.
EMA publishes EU strategy to 2028
European Pharmaceutical Review
OCTOBER 10, 2024
A draft joint EU network strategy to 2028 has been published by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). This is updated strategy replaces the original five-year strategy, which was developed to cover from 2021 to 2025 (EMANS 2025). Revised strategy – adapting to change The draft strategy covers the following focus areas up to 2028: Accessibility to support pathways for medicine access in the EU Leveraging data, digitalisation and artificial intelligen
Point Solution Fatigue? Zooming Out to the Population Level Can Help
MedCity News
OCTOBER 8, 2024
The best solutions, in summary, are those that facilitate better outcomes while reducing costs — combining member health and satisfaction with healthcare savings. The post Point Solution Fatigue? Zooming Out to the Population Level Can Help appeared first on MedCity News.
Scholar Rock preps filings after SMA antibody clears trial
pharmaphorum
OCTOBER 8, 2024
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The stock rocketed 362% after the announcement, taking Scholar Rock's market cap above $2.7 billion, as analysts started to talk about a blockbuster sales opportunity for the selective myostatin inhibitor.
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Fierce Pharma
OCTOBER 11, 2024
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.
NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia
Pharmaceutical Technology
OCTOBER 7, 2024
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs?
MedCity News
OCTOBER 9, 2024
If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California. The post Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? appeared first on MedCity News.
Organizational Resilience: Easy to Get, Hard to Keep
ALULA
OCTOBER 7, 2024
The Billion-Dollar Question In today's fast-paced business environment, organizational resilience isn't just a buzzword—it's a key driver of success. Consider this: companies with high organizational resilience outperform their peers by an average of 30% in long-term shareholder returns.
Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease
Fierce Pharma
OCTOBER 8, 2024
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a new positive readout can return Keytruda to glory in head and neck cancer about two years after a prior failure.
Patient Portals: Best Practices for Protecting Online Data
Referral MD
OCTOBER 7, 2024
Securing Patient Portals: Best Practices for Protecting Online Records 33.33% of patient portals have privacy concerns that create a sense of distrust among many providers and patients. What are the best practices for data security? Most healthcare organizations and other care providers still struggle to find the balance between offering an easy-to-use interface and maintaining data integrity.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say
MedCity News
OCTOBER 6, 2024
Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to enact stricter policies that require payers to operate on faster timelines, as well as provide more transparency into their reasons for denying claims. The post Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say appeared first on MedCity News.
Facing Potential Drug Shortages, FDA Delays Enforcement of DSCSA Compliance Deadline, with Stipulations
Pharmaceutical Commerce
OCTOBER 11, 2024
The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
Fierce Pharma
OCTOBER 10, 2024
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. | As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio.
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
PharmaVoice
OCTOBER 7, 2024
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Look Who’s Talking at HLTH
MedCity News
OCTOBER 9, 2024
HLTH, scheduled for October 20-23 in Las Vegas, spotlights individuals across the healthcare ecosystem from high-powered executives such as the head of health technology at tech and social media giant Meta to Lenny Kravitz, who will talk about health equity. Here’s a preview of who will be speaking at HLTH, what they’ll be talking about, where and when.
Sanofi in talks to sell stake in consumer health spinout
pharmaphorum
OCTOBER 11, 2024
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.The French pharma group confirmed this morning that it has entered into talks with US-based Clayton Dubilier & Rice to sell a controlling 50% stake in the unit for what has been estimated by Reuters to be in the region of €15 billion ($16.4 billion).
Evonik telegraphs another 260 layoffs amid multiyear reorganization
Fierce Pharma
OCTOBER 11, 2024
Earlier this year, Evonik unveiled a restructuring project that will result in up to 2,000 layoffs. | After Evonik in March unveiled a restructuring project that will result in up to 2,000 layoffs, the company is now announcing another round of job cuts as it retools portions of its drug ingredients and nutrition businesses.
EMA starts review into hair loss drugs about potential link to suicidal thoughts
Pharmaceutical Technology
OCTOBER 7, 2024
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
Let's personalize your content